RHO Ventures VI LP

This profile gathers the share dealings of RHO Ventures VI LP across 2 companies, led by Bluefly Inc and Tvardi Therapeutics, Inc. Between 25 February 2010 and 31 March 2017, the trades on record add up to 10 filings.

In open-market terms, that means 5 purchases worth €12.3M on one side and 1 sale worth €70k on the other. On balance, insiders were net buyers of €12.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants. In 2017 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €1.1M. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 4 purchases show a median change of -12.9%, with the price up in 25% of them. These figures describe past trades and do not predict future prices.

The record was last updated on 3 April 2017 with an open-market purchase (€8.5M) in Tvardi Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.